Archives

You can view an archive of all our press releases below:

• Iroko Pharmaceuticals’ Submicron NSAIDs Demonstrate Efficacy at Lower Doses in Studies in Patients with Acute and Chronic Pain
• Iroko Pharmaceuticals Announces Acceptance for NDA Filing of Lower Dose Submicron Diclofenac for the Treatment of Mild to Moderate Acute Pain in Adults
• Philadelphia Mayor Nutter and Local Officials Celebrate Opening of Iroko Pharmaceuticals’ Environmentally Friendly Global Headquarters in The Navy Yard
• Iroko Pharmaceuticals and University of Pennsylvania Launch Multi-Year Young Scientist Scholarship Program
• Results from a Phase 3 Study Show Iroko’s Investigational Submicron Indomethacin Provided Effective Pain Relief at Lower Doses
• Novel, Submicron Particle, Lower-Dose Diclofenac Demonstrated Relief of Acute Pain in Phase 3 Study
• Iroko Pharmaceuticals Makes Strategic Additions to Executive Team with Appointment of Clarence L. Young, M.D. as Chief Medical Officer and Moji James as General Counsel
• Pain Medicines in Novel Formulations Show Potential for Relief at Lower Doses
• Novel Formulation of Diclofenac Provides Pain Relief at Lower Doses
• Liberty/Synterra & Iroko Pharmaceuticals Break Ground on a 56,412 Square Foot Sustainable Office Building at the Philadelphia Navy Yard
• Early Results Of Development Program in Nano-Formulated NSAIDs Show Potential For Faster Pain Relief At Lower Doses
• Iroko Divests Antibiotic Product in Canada
• Iroko Selects Aptuit As Contract Manufacturing Partner
• Iroko Names David U'Prichard to Company's Board
• Iroko Pharmaceuticals Announces Financial Investment in New Product Development
• iCeutica Completes GMP Scale-Up for its Nano-Sized Products
• Chief Medical Officer Announces Intention to Retire
• Iroko Pharmaceuticals Acquires Canadian Rights to Lilly Anti-Infective Product
• Iroko Pharmaceuticals Acquires Nano-Reformulated Products from iCeutica
• Iroko Pharmaceuticals Appoints John Vavricka as President and Chief Executive Officer
• Iroko Pharmaceuticals Acquires Rights to Two Pharmaceutical Products from Merck & Co., Inc.